132 related articles for article (PubMed ID: 16040302)
1. Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions.
Naka T; Boltze C; Kuester D; Samii A; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Roessner A
Am J Clin Pathol; 2005 Aug; 124(2):288-94. PubMed ID: 16040302
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.
Naka T; Boltze C; Kuester D; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Am J Clin Pathol; 2004 Dec; 122(6):926-30. PubMed ID: 15539385
[TBL] [Abstract][Full Text] [Related]
3. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability.
Naka T; Boltze C; Samii A; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Cancer; 2003 Nov; 98(9):1934-41. PubMed ID: 14584077
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas.
Saad AG; Collins MH
Pediatr Dev Pathol; 2005; 8(3):362-8. PubMed ID: 16010499
[TBL] [Abstract][Full Text] [Related]
5. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
7. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract][Full Text] [Related]
8. Histogenesis of intralesional fibrous septum in chordoma.
Naka T; Boltze C; Kuester D; Samii A; Herold C; Ostertag H; Iwamoto Y; Odae Y; Tsuneyoshi M; Roessner A
Pathol Res Pract; 2005; 201(6):443-7. PubMed ID: 16136750
[TBL] [Abstract][Full Text] [Related]
9. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases.
Hoch BL; Nielsen GP; Liebsch NJ; Rosenberg AE
Am J Surg Pathol; 2006 Jul; 30(7):811-8. PubMed ID: 16819322
[TBL] [Abstract][Full Text] [Related]
10. Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression.
Naka T; Boltze C; Kuester D; Schulz TO; Schneider-Stock R; Kellner A; Samii A; Herold C; Ostertag H; Roessner A
Cancer; 2005 Sep; 104(6):1255-63. PubMed ID: 16078265
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma.
Naka T; Boltze C; Samii A; Samii M; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Histopathology; 2009 Apr; 54(5):607-13. PubMed ID: 19302530
[TBL] [Abstract][Full Text] [Related]
12. [Pathology of myxoid bone tumors of the skull base].
Gavril C; Bouvier C; Liprandi A; Dufour H; Peragut JC; Zanaret M; Figarella-Branger D
Ann Pathol; 2002 Sep; 22(4):259-66. PubMed ID: 12410148
[TBL] [Abstract][Full Text] [Related]
13. Proliferative activities in conventional chordoma: a clinicopathologic, DNA flow cytometric, and immunohistochemical analysis of 17 specimens with special reference to anaplastic chordoma showing a diffuse proliferation and nuclear atypia.
Naka T; Fukuda T; Chuman H; Iwamoto Y; Sugioka Y; Fukui M; Tsuneyoshi M
Hum Pathol; 1996 Apr; 27(4):381-8. PubMed ID: 8617482
[TBL] [Abstract][Full Text] [Related]
14. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue.
Tirabosco R; Mangham DC; Rosenberg AE; Vujovic S; Bousdras K; Pizzolitto S; De Maglio G; den Bakker MA; Di Francesco L; Kalil RK; Athanasou NA; O'Donnell P; McCarthy EF; Flanagan AM
Am J Surg Pathol; 2008 Apr; 32(4):572-80. PubMed ID: 18301055
[TBL] [Abstract][Full Text] [Related]
15. Clinical and histopathologic features of chordomas in children and young adults.
Ridenour RV; Ahrens WA; Folpe AL; Miller DV
Pediatr Dev Pathol; 2010; 13(1):9-17. PubMed ID: 19348512
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
[TBL] [Abstract][Full Text] [Related]
17. Chordomas: a histological and immunohistochemical study of cases with and without recurrent tumors.
Sell M; Sampaolo S; Di Lorio G; Theallier A
Clin Neuropathol; 2004; 23(6):277-85. PubMed ID: 15584212
[TBL] [Abstract][Full Text] [Related]
18. Chordoma: the nonsarcoma primary bone tumor.
Chugh R; Tawbi H; Lucas DR; Biermann JS; Schuetze SM; Baker LH
Oncologist; 2007 Nov; 12(11):1344-50. PubMed ID: 18055855
[TBL] [Abstract][Full Text] [Related]
19. [Chordoma].
Solov'ev IuN
Arkh Patol; 1999; 61(5):65-9. PubMed ID: 10598266
[TBL] [Abstract][Full Text] [Related]
20. [Embryology and pathology of the human notochord].
Salisbury JR
Ann Pathol; 2001 Dec; 21(6):479-88. PubMed ID: 11910935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
